Herpes Simplex Virus Treatment Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Drug Type ; By Distribution Channel ; By Region

Description

Global Herpes Simplex Virus (HSV) Treatment Market Size Set to Touch USD 2.17 Billion by 2029.

Global herpes simplex virus (HSV) treatment market is flourishing because of an increasing development of HSV testing and medications and rising prevalence of HSV infections.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global herpes simplex virus (HSV) treatment market size at USD 1.73 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global herpes simplex virus (HSV) treatment market size to grow at a CAGR of 3.83% reaching a value of USD 2.17 billion by 2029. Major growth drivers for the global herpes simplex virus (HSV) treatment market include an increasing prevalence of herpes infections, rising awareness about available treatment options, and the growing demand for effective therapies. Increasing adoption of antiviral drugs and the development of novel treatment approaches are further contributing to market growth. Herpes simplex, a widespread strain of the herpes virus, affects a substantial portion of the global population, with approximately 3.7 billion individuals estimated to be impacted. This highly contagious infection can be transmitted through various bodily fluids such as saliva, vaginal secretions, or semen, often without the carrier's knowledge. Also, there has been a noticeable rise in human herpesvirus lytic reactivation among COVID-19 patients, including those who have received vaccinations, during the forecast period. However, prevalent side effects of most used herpes medications are anticipated to restrain the global herpes simplex virus (HSV) treatment market growth.

Global Herpes Simplex Virus (HSV) Treatment Market - Overview:

The global herpes simplex virus (HSV) treatment market refers to the collective market for pharmaceutical products, therapies, and interventions used in the management and treatment of herpes infections caused by the herpes simplex virus. This market encompasses various treatment options, including antiviral medications, topical creams, vaccines, and other therapeutic approaches aimed at reducing the severity of outbreaks, alleviating symptoms, and suppressing viral replication. The market is driven by the increasing prevalence of herpes infections globally, the growing demand for effective treatment options, and ongoing research and development efforts to improve therapeutic outcomes.

Impact of COVID-19 on Global Herpes Simplex Virus (HSV) Treatment Market:

COVID-19 pandemic had a dual impact on the global herpes simplex virus (HSV) treatment market. On the one hand, the increased focus on healthcare and hygiene practices raised awareness about the importance of managing infectious diseases like HSV. It increased the demand for HSV treatments. On the other hand, the diversion of healthcare resources and disruption of supply chains as the pandemic posed challenges for accessing and delivering HSV treatments. Also, the prioritization of COVID-19-related research and development temporarily slowed down advancements in HSV treatment options. The overall impact of COVID-19 on the global herpes simplex virus (HSV) treatment market remains complex and may vary across regions.

Global Herpes Simplex Virus (HSV) Treatment Market - By Drug Type:

Based on drug type, the global herpes simplex virus (HSV) treatment market is divided into Acyclovir, Valacyclovir, and Famciclovir segments. Valacyclovir segment held the highest share in the global herpes simplex virus treatment market during 2022. This can be attributed to its cost-effectiveness, wide availability, and remarkable efficacy in inhibiting the replication of the herpes virus within the body, thus effectively managing the symptoms associated with herpes outbreaks. Valacyclovir is particularly favored for its superior absorption rate compared to acyclovir, making it a preferred choice for treating cold sores, as oral acyclovir is susceptible to rapid breakdown by the liver. Also, a study published in the American Journal of Ophthalmology has demonstrated the comparable effectiveness of a 500 mg valacyclovir dose in preventing the recurrence of HSV eye disease to that of an 800 mg acyclovir dose. Meanwhile, the acyclovir segment is expected to witness fastest growth during the forecast period. This can be attributed to the widespread acceptance of acyclovir as the industry benchmark for the treatment of herpes infections. Also, the market's growth is fueled by the introduction of over-the-counter drugs for infection treatment.

Competitive Landscape:

Major players operating in the global herpes simplex virus treatment market include: Abbott Laboratories, Pfizer Inc., Amneal Pharmaceuticals Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd, Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris Inc., and Emcure Pharmaceuticals Limited. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Herpes Simplex Virus (HSV) Treatment Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Herpes Simplex Virus (HSV) Treatment Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Product Code: BWC23615

1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Executive Summary

3. Global Herpes Simplex Virus (HSV) Treatment Market Insights

3.1. Industry Value Chain Analysis
3.2. DROC Analysis
- 3.2.1. Growth Drivers
  - 3.2.1.1. Increasing prevalence of herpes simplex virus infections
  - 3.2.1.2. Rising development of HSV testing and medications
- 3.2.2. Restraints
  - 3.2.2.1. Prevalent side effects of most used herpes medications
- 3.2.3. Opportunities
  - 3.2.3.1. Increase in R&D activities
  - 3.2.3.2. High growth potential in developing economies
- 3.2.4. Challenges
  - 3.2.4.1. Stigma associated with herpes simplex virus
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry
3.6. Price Point Analysis: Global Automotive Memory, 2019-2022

4. Global Herpes Simplex Virus (HSV) Treatment Market Overview

4.1. Market Size & Forecast by Value, 2019-2029
- 4.1.1. By Value (USD Billion)
4.2. Market Share & Forecast
- 4.2.1. By Type
  - 4.2.1.1. Herpes simplex virus-1 infection
  - 4.2.1.2. Herpes simplex virus-2 infection
- 4.2.2. By Drug Type
  - 4.2.2.1. Acyclovir
  - 4.2.2.2. Valacyclovir
  - 4.2.2.3. Famciclovir
- 4.2.3. By Distribution Channel
  - 4.2.3.1. Hospital pharmacies
  - 4.2.3.2. Drug store and retail pharmacies
  - 4.2.3.3. Online providers
- 4.2.4. By Region
  - 4.2.4.1. North America
  - 4.2.4.2. Europe
  - 4.2.4.3. Asia Pacific (APAC)
  - 4.2.4.4. Latin America (LATAM)
  - 4.2.4.5. Middle East and Africa (MEA)

5. North America Herpes Simplex Virus (HSV) Treatment Market

5.1. Market Size & Forecast by Value, 2019-2029
- 5.1.1. By Value (USD Billion)
5.2. Market Share & Forecast
- 5.2.1. By Type
- 5.2.2. By Drug Type
- 5.2.3. By Distribution Channel
- 5.2.4. By Country
  - 5.2.4.1. United States
  - 5.2.4.1.1. By Type
  - 5.2.4.1.2. By Drug Type
  - 5.2.4.1.3. By Distribution Channel
  - 5.2.4.2. Canada
  - 5.2.4.2.1. By Type
  - 5.2.4.2.2. By Drug Type
  - 5.2.4.2.3. By Distribution Channel

6. Europe Herpes Simplex Virus (HSV) Treatment Market

6.1. Market Size & Forecast by Value, 2019-2029
- 6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Drug Type
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
  - 6.2.4.1. Germany
  - 6.2.4.1.1. By Type
  - 6.2.4.1.2. By Drug Type
  - 6.2.4.1.3. By Distribution Channel
  - 6.2.4.2. United Kingdom
  - 6.2.4.2.1. By Type
  - 6.2.4.2.2. By Drug Type
  - 6.2.4.2.3. By Distribution Channel
  - 6.2.4.3. Italy
  - 6.2.4.3.1. By Type
  - 6.2.4.3.2. By Drug Type
  - 6.2.4.3.3. By Distribution Channel
  - 6.2.4.4. France
  - 6.2.4.4.1. By Type
  - 6.2.4.4.2. By Drug Type
  - 6.2.4.4.3. By Distribution Channel
  - 6.2.4.5. Spain
  - 6.2.4.5.1. By Type
  - 6.2.4.5.2. By Drug Type
  - 6.2.4.5.3. By Distribution Channel
  - 6.2.4.6. The Netherlands
  - 6.2.4.6.1. By Type
  - 6.2.4.6.2. By Drug Type
  - 6.2.4.6.3. By Distribution Channel
  - 6.2.4.7. Rest of Europe
  - 6.2.4.7.1. By Type
  - 6.2.4.7.2. By Drug Type
  - 6.2.4.7.3. By Distribution Channel

7. Asia-Pacific Herpes Simplex Virus (HSV) Treatment Market

7.1. Market Size & Forecast by Value, 2019-2029
- 7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Drug Type
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
  - 7.2.4.1. China
  - 7.2.4.1.1. By Type
  - 7.2.4.1.2. By Drug Type
  - 7.2.4.1.3. By Distribution Channel
  - 7.2.4.2. India
  - 7.2.4.2.1. By Type
  - 7.2.4.2.2. By Drug Type
  - 7.2.4.2.3. By Distribution Channel
  - 7.2.4.3. Japan
  - 7.2.4.3.1. By Type
  - 7.2.4.3.2. By Drug Type
  - 7.2.4.3.3. By Distribution Channel
  - 7.2.4.4. South Korea
  - 7.2.4.4.1. By Type
  - 7.2.4.4.2. By Drug Type
  - 7.2.4.4.3. By Distribution Channel
  - 7.2.4.5. Australia & New Zealand
  - 7.2.4.5.1. By Type
  - 7.2.4.5.2. By Drug Type
  - 7.2.4.5.3. By Distribution Channel
  - 7.2.4.6. Indonesia
  - 7.2.4.6.1. By Type
  - 7.2.4.6.2. By Drug Type
  - 7.2.4.6.3. By Distribution Channel
  - 7.2.4.7. Malaysia
  - 7.2.4.7.1. By Type
  - 7.2.4.7.2. By Drug Type
  - 7.2.4.7.3. By Distribution Channel
  - 7.2.4.8. Singapore
  - 7.2.4.8.1. By Type
  - 7.2.4.8.2. By Drug Type
  - 7.2.4.8.3. By Distribution Channel
  - 7.2.4.9. Philippines
  - 7.2.4.9.1. By Type
  - 7.2.4.9.2. By Drug Type
  - 7.2.4.9.3. By Distribution Channel
  - 7.2.4.10. Vietnam
  - 7.2.4.10.1. By Type
  - 7.2.4.10.2. By Drug Type
  - 7.2.4.10.3. By Distribution Channel
  - 7.2.4.11. Rest of APAC
  - 7.2.4.11.1. By Type
  - 7.2.4.11.2. By Drug Type
  - 7.2.4.11.3. By Distribution Channel

8. Latin America Herpes Simplex Virus (HSV) Treatment Market

8.1. Market Size & Forecast by Value, 2019-2029
- 8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Drug Type
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
  - 8.2.4.1. Brazil
  - 8.2.4.1.1. By Type
  - 8.2.4.1.2. By Drug Type
  - 8.2.4.1.3. By Distribution Channel
  - 8.2.4.2. Mexico
  - 8.2.4.2.1. By Type
  - 8.2.4.2.2. By Drug Type
  - 8.2.4.2.3. By Distribution Channel
  - 8.2.4.3. Argentina
  - 8.2.4.3.1. By Type
  - 8.2.4.3.2. By Drug Type
  - 8.2.4.3.3. By Distribution Channel
  - 8.2.4.4. Peru
  - 8.2.4.4.1. By Type
  - 8.2.4.4.2. By Drug Type
  - 8.2.4.4.3. By Distribution Channel
  - 8.2.4.5. Colombia
  - 8.2.4.5.1. By Type
  - 8.2.4.5.2. By Drug Type
  - 8.2.4.5.3. By Distribution Channel
  - 8.2.4.6. Rest of LATAM
  - 8.2.4.6.1. By Type
  - 8.2.4.6.2. By Drug Type
  - 8.2.4.6.3. By Distribution Channel

9. Middle East & Africa Herpes Simplex Virus (HSV) Treatment Market

9.1. Market Size & Forecast by Value, 2019-2029
- 9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Drug Type
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
  - 9.2.4.1. Saudi Arabia
  - 9.2.4.1.1. By Type
  - 9.2.4.1.2. By Drug Type
  - 9.2.4.1.3. By Distribution Channel
  - 9.2.4.2. UAE
  - 9.2.4.2.1. By Type
  - 9.2.4.2.2. By Drug Type
  - 9.2.4.2.3. By Distribution Channel
  - 9.2.4.3. Qatar
  - 9.2.4.3.1. By Type
  - 9.2.4.3.2. By Drug Type
  - 9.2.4.3.3. By Distribution Channel
  - 9.2.4.4. Kuwait
  - 9.2.4.4.1. By Type
  - 9.2.4.4.2. By Drug Type
  - 9.2.4.4.3. By Distribution Channel
  - 9.2.4.5. South Africa
  - 9.2.4.5.1. By Type
  - 9.2.4.5.2. By Drug Type
  - 9.2.4.5.3. By Distribution Channel
  - 9.2.4.6. Nigeria
  - 9.2.4.6.1. By Type
  - 9.2.4.6.2. By Drug Type
  - 9.2.4.6.3. By Distribution Channel
  - 9.2.4.7. Algeria
  - 9.2.4.7.1. By Type
  - 9.2.4.7.2. By Drug Type
  - 9.2.4.7.3. By Distribution Channel
  - 9.2.4.8. Rest of MEA
  - 9.2.4.8.1. By Type
  - 9.2.4.8.2. By Drug Type
  - 9.2.4.8.3. By Distribution Channel

10. Competitive Landscape

10.1. List of Key Players and Their Offerings
10.2. Global Herpes Simplex Virus (HSV) Treatment Products Company Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Herpes Simplex Virus (HSV) Treatment Market

12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis)

12.1. Abbott Laboratories
12.2. Pfizer, Inc.
12.3. Amneal Pharmaceuticals, Inc.
12.4. GlaxoSmithKline PLC
12.5. Teva Pharmaceuticals Industries Ltd.
12.6. Glenmark Pharmaceuticals Limited
12.7. Fresenius SE & Co. KGaA
12.8. Novartis AG
12.9. Viatris, Inc.
12.10. Emcure Pharmaceuticals Limited
12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

14.1. Qualitative Research
- 14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
- 14.3.1. Secondary Research
- 14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumption & Limitation